Related Experiment Videos
Cost-effective management of heart failure
1Department of Medicine, University of California, San Francisco, USA.
Clinical Cardiology
|March 1, 1996
Summary
Heart failure impacts millions, costing billions annually, primarily due to hospitalizations. Angiotensin-converting enzyme (ACE) inhibitors are cost-effective treatments that reduce mortality and hospital stays.
Area of Science:
- Cardiology
- Health Economics
Background:
- Heart failure affects over 2 million Americans, with 400,000 new diagnoses yearly.
- The economic burden exceeds $10 billion annually, with hospitalization and nursing home care comprising the majority of costs.
Purpose of the Study:
- To evaluate the cost-effectiveness of management strategies for heart failure.
- To identify methods for reducing healthcare expenditures associated with heart failure.
Main Methods:
- Review of current treatment protocols and healthcare spending data for heart failure.
- Analysis of the impact of medications like angiotensin-converting enzyme (ACE) inhibitors on patient outcomes and costs.
Main Results:
- Angiotensin-converting enzyme (ACE) inhibitors demonstrate significant cost-effectiveness by reducing mortality and hospitalization rates.
- Hospitalization accounts for approximately 75% of heart failure-related costs.
- Nursing home care represents nearly 20% of the total economic burden.
Conclusions:
- Cost-effective heart failure management should prioritize preventing hospital admissions.
- Optimizing the utilization of diagnostic tests can lead to additional healthcare savings.
- ACE inhibitors are a vital, cost-effective tool in managing heart failure and reducing patient mortality.